<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Among a variety of central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) manifestations of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, the most serious one is <z:hpo ids='HP_0000726'>progressive dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, there has been no effective treatment to prevent the progression of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The present studies have examined the efficacy of low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi> therapy for the <z:hpo ids='HP_0000726'>progressive dementia</z:hpo> in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="3" pm="."><plain>Six patients with the progressive type of neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease were treated with low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (7.5-15 mg/week) </plain></SENT>
<SENT sid="4" pm="."><plain>Neurological findings, psychological findings, brain MRI and IL-6 in cerebrospinal fluid were evaluated at the start and one year after the initiation of the therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the 6 patients were refractory to the conventional therapy for neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="6" pm="."><plain>The progression of neuropsychological abnormalities such as <z:hpo ids='HP_0000726'>dementia</z:hpo> was not recognized after one year from the initiation of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Consistently, IL-6 levels in cerebrospinal fluid were significantly decreased after one year from the initiation of therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Six months after the discontinuation of low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, progression of neuropsychological abnormalities such as <z:hpo ids='HP_0000726'>dementia</z:hpo> was recognized, and IL-6 levels in cerebrospinal fluid were significantly increased </plain></SENT>
<SENT sid="9" pm="."><plain>These findings may suggest the suppression of the ongoing inflammatory process in the intracranial lesions by <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>These results suggest that low-dose weekly <z:chebi fb="0" ids="44185">methotrexate</z:chebi> therapy may be a new promising method for the treatment of the progressive type of neuro-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>